v3.25.0.1
Revenue (Tables)
12 Months Ended
Dec. 31, 2024
Revenue from Contract with Customer [Abstract]  
Summary of Changes in Balances of Receivables and Contract Liability The following table presents changes in the balances of receivables and contract liabilities related to revenue generating agreements during the year ended December 31, 2024:

 

(in thousands)

 

December 31, 2023

 

 

Additions

 

 

Deductions

 

 

December 31, 2024

 

Contract Assets:

 

 

 

 

 

 

 

 

 

 

 

 

Accounts receivable

 

$

32,064

 

 

$

98,430

 

 

$

(126,520

)

 

$

3,974

 

Contract Liabilities:

 

 

 

 

 

 

 

 

 

 

 

 

Deferred revenue

 

$

87,325

 

 

$

97,599

 

 

$

(152,806

)

 

$

32,118

 

Schedule of Revenue

The following table summarizes the Company’s revenue for the periods indicated. Approximately $138.4 million, $154.9 million and $192.7 million of total revenue represents revenue derived from foreign countries for the years ended December 31, 2024, 2023 and 2022, respectively.

 

For the Year Ended December 31,

 

(in thousands)

2024

 

 

2023

 

 

2022

 

Collaboration revenue:

 

 

 

 

 

 

 

 

 

CSL Seqirus

$

138,389

 

 

$

154,264

 

 

$

154,425

 

Vinbiocare

 

 

—

 

 

 

—

 

 

 

24,571

 

Janssen

 

 

—

 

 

 

660

 

 

 

9,201

 

Ultragenyx

 

—

 

 

 

1,837

 

 

 

3,739

 

Israel Ministry of Health

 

 

—

 

 

 

—

 

 

 

12,500

 

Other

 

 

—

 

 

 

987

 

 

 

1,319

 

Total collaboration revenue

 

$

138,389

 

 

$

157,748

 

 

$

205,755

 

Grant revenue:

 

 

 

 

 

 

 

 

 

BARDA

 

$

13,921

 

 

$

9,051

 

 

$

244

 

Total grant revenue

$

13,921

 

 

$

9,051

 

 

$

244